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Available online 28 September 2016Frontotemporal dementia with parkinsonism linked to chromosome 17q21.2 (FTDP-17) is an autosomal-domi-
nant neurodegenerative disorder. Mutations in the MAPT (microtubule-associated protein tau)-gene can cause
FTDP-17, but the underlying pathomechanisms of the disease are still unknown. Induced pluripotent stem cells
(iPSCs) hold great promise to model FTDP-17 as such cells can be differentiated in vitro to the required cell type.
Furthermore, gene-editing approaches allow generating isogenic gene-corrected controls that can be used as a
very speciﬁc control. Here, we report the generation of genetically corrected iPSCs from a 57-year-old female
FTD-17 patient carrying an P301L mutation in the MAPT-gene.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Resource table:ame of stem cell line H251 C3 GC
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Previously,wehave generated an induced pluripotent stemcell (iPSC)
line (H251 C3) from a symptomatic, 57-year-old woman carrying a. This is an open access article underheterozygous P301L mutation in the microtubule-associated protein tau
(MAPT) gene (Rasmussen et al., 2016). Reprogramming was performed
by electroporation of three episomal plasmids encoding hOCT4, hSOX2,
hKLF4, hL-MYC, and hLIN28 (Okita et al., 2011; Takahashi et al., 2007).
Here, we generated a gene-corrected clone of H251 C3 using the
CRISPR/Cas9 technology, where the mutated triplet CTG (Leucine) was
corrected to the wild-type triplet CCG (Proline) using a single stranded
oligodeoxynucleotide (ssODN) as a homologous template (Fig. 1A).
Successful gene-correction was validated by sequencing (Fig. 1B).
Sequencing analysis of the region around the CRISPR cutting site
conﬁrmed that no further cutting occurred and that the DNA sequence
remained intact without frameshift or other mutations. We ﬁnally
ensured that the cells were still pluripotent after gene-correction
(Fig. 1C, D and E) and showed a normal karyotype (Fig. 1F).
2. Materials and methods
2.1. CRISPR design
Isogenic gene-corrected controls were obtained using the
CRISPRs/Cas9 system in combination with an ssODN serving asthe CC BY-NC-ND license
Fig. 1. Characterization of iPSCs. (A) Schematic of the gene editing strategy used to correct the MAPT P301L mutation in exon 10 using the CRISPR/Cas9 system in combination with an
ssODN as homologous donor construct. (B) Sequencing result of the iPSC line H251 C3 showing a heterozygous C N T mutation (P301L mutation; upper panel). After gene correction
(H251 C3 GC), the mutation was no longer present (lower panel). (C) Immunocytochemistry analysis of the pluripotency markers OCT4 (red), TRA1-60 (green) and SSEA4 (green),
scale bars = 100 μM. (D) Quantitative PCR analysis of pluripotency genes from the gene-corrected line and a previously established iPSC control line BIONi010-C compared to
ﬁbroblasts (set to 1). (E) Immunocytochemistry for proteins representative of the three germ layers, TUJ1 (ectoderm), SMA (mesoderm) and AFP (endoderm), after in vitro
differentiation by embryoid body formation, scale bars = 200 μM. (F) Representative karyotype of the iPSC line H251 C3 GC (46, XX).
557N. Nimsanor et al. / Stem Cell Research 17 (2016) 556–559homologous template covering the site of the mutation. A CRISPR
targeting exon 10 of the MAPT gene was designed at http://crispr.
mit.edu/. The CRISPRs were generated in a single plasmid (a giftfrom Feng Zhang) containing both sgRNA and the Cas9 (pSpCas9(BB)-
2A-Puro (PX459); Addgene plasmid #62988) following the
protocol from Ran et al. (2013). The following sequence was
Table 1
Antibodies used for immunochemistry.
Antibodies and
host species Dilution
Company and
catalog number
Pluripotency Goat anti-OCT4 1:500 Santa Cruz, sc-8628
Rabbit anti-NANOG 1:100 Millipore, AB5731
Mouse anti-SSEA4 1:500 BioLegend, 330402
Mouse anti TRA-1-60 1:500 BioLegend, 330602
Mouse anti TRA-1-81 1:500 BioLegend, 330702
In vitro
differentiation
Mouse anti-Smooth
muscle actin (SMA)
1:500 Dako, M0851
Rabbit
anti-Alpha-1-fetoprotein
(AFP)
1:500 Dako, A0008
Mouse anti-Beta-III-tubulin
(TUJ1)
1:500 Sigma-Aldrich, T8660
558 N. Nimsanor et al. / Stem Cell Research 17 (2016) 556–559recognized by the CRISPR: GATAATATCAAACACGTCCTGGG (T =
mutation site).
2.2. Nucleofection
iPSCs were cultured on 100 mm dishes coated with Matrigel
(Corning Bioscience) in E8 medium and detached using accutase
(Gibco) when they reached a conﬂuency of 70–90%. A total of 1.5 ×
106 cells were co-nucleofected with 10 μg of the CRISPR/Cas9 encoding
plasmid and 1 μL of 100 μMssODNusing the P3 Primary Cell Kit (Lonza)
using the nucleofection programCA167 following to themanufacturer's
instructions (Lonza). iPSCs were subsequently transferred back to a
Matrigel-coated 100 mm dish in E8 medium supplemented with
1:200 diluted Revita cell supplement (Gibco). At 4 h post-nucleofection,
cells were subjected to selection medium (E8 medium containing
1 μg/mL puromycin) for 20 h and then allowed to recover for a
week in normal E8 medium. Finally, colonies were then picked and
expanded for genotyping.
2.3. Genotyping
DNA for genotyping was extracted using the prepGem kit from
ZyGEM. PCR genotyping was performed using TEMPase Hot Start DNA
Polymerase (Ampliqon) according to the manufacturer's instructions
at an annealing temperature of 62 °C. The following screening primers
were designed covering the P301L mutation in the MAPT gene: Exon
10 forward 5′-TCACTCATCGAAAGTGGAGG-3′ and Exon 10 reverse 5′-
CAGTGTCTCGCAAGTGTACG-3′. The PCR products were digested using
XmaI for 1 h to detect gene-corrected clones (correction of themutation
produces an XmaI restriction enzyme cutting site). Positive clones were
then sequenced using the forward primer to conﬁrm correction of the
mutation.
2.4. qRT-PCR analysis of stem cell markers
Total RNA was puriﬁed from H251 C3 GC iPSCs, ﬁbroblasts and the
iPSC line BIONi010-C (Rasmussen et al., 2014) as a positive control
using RNeasy mini kit (Qiagen). Conversion to cDNA was performed
with RevertAid First Strand cDNA synthesis kit (Thermo Scientiﬁc).
qPCR analysis was carried out using the TaqMan primers GAPDH
Hs03929097_g1, NANOG Hs02387400_g1, OCT4 Hs00999632_g1,
TDGF1 Hs02339497_g1, DMNT3B Hs00171876_m1 and GABRB3
Hs00241459_m1 (Thermo Scientiﬁc). Data was analyzed using the
2−ΔΔCt method relative to GAPDH with ﬁbroblasts as a reference
(set to 1).
2.5. Immunostaining of pluripotency markers
Cells were seeded on matrigel-coated coverslips. After 2 days, the
cells were ﬁxed at room temperature with 4% paraformaldehyde in
PBS for 10 min, permeabilized with 0.1% Triton X-100 and blocked
for unspeciﬁc binding with 2% BSA in PBS for 1 h. Immunostaining
was performed with primary antibodies against OCT4, NANOG,
TRA-1-60, TRA-1-81, and SSEA4 (Table 1). After incubation with
the primary antibody, the cells were washed 3 times with PBS and
then incubated with ﬂuorescence-conjugated secondary antibodies
Alexa ﬂuor 488 (goat anti-mouse, 1:1000) or Cyanine 3 (goat anti-
rabbit, 1:1000) for 1 h (both Life technologies). The cells were
mounted on glass slides with mounting solution-containing DAPI
(Life Technologies).
2.6. In vitro differentiation
iPSCs were dissociated with EDTA (Gibco) and allowed to form ag-
gregates in non-coated cell culture dishes with E8 medium. On day 2,
the E8 mediumwas changed to E6medium (E6medium= E8mediumwithout FGF2 and TGF-β1). On day 7, the aggregateswere transferred to
matrigel-coated dishes and medium was switched to differentiation
medium. For mesodermal differentiation: DMEM/F12 containing 10%
FBS, 1% L-glutamine, and 1% non-essential amino acids (all Gibco). For
endodermal differentiation: MCDB131-1 containing 0.5% BSA, 0.1%
pen/strep, 3 μM CHIR99021 (Selleckchem), 100 ng/mL Activin A (Cell
Guidance). For ectodermal differentiation: DMEM/F12 mixed with
neurobasal medium in a ratio of 1:1, 1X B27, 1X N2, and 1% L-glutamine
(all Gibco), 10 μM SB 431542 and 0.1 μM LDN 193189 (both
Selleckchem). Cells were ﬁxed for immunocytochemistry on day 21.
ICC analysis was performed with the antibodies against TUJ1, SMA and
AFP (Table 1).
2.7. Karyotyping
iPSCs and ﬁbroblasts were treated for 1 h with KaryoMAX colcemid
(Life Technologies) followed by hypotonic treatment and then harvest-
ed in fresh ﬁxative containing 25% acetic acid and 75% methanol.
Karyotyping was performed on G-banded metaphase chromosomes
using standard cytogenetic procedures.
2.8. Veriﬁcation and authentication
An intact genome was demonstrated by karyotyping using G-
banding of 15 mitoses. Analysis was performed at the Institute of
Medical Genetics and Applied Genomics, University of Tübingen,
Germany. The results showed a normal 46, XX karyotype, free of any
discernible abnormalities iPSC line identity (Fig. 1F).
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